Literature DB >> 106013

Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.

M M Lieberman, D C McKissock, G L Wright.   

Abstract

Passive protection of mice against Pseudomonas aeruginosa using specific antisera and immunoglobulin fractions induced by immunizing rabbits with a ribosomal vaccine is reported. The results demonstrated that protection by the ribosomal vaccine against challenge with live organisms can be serum mediated. Previous work has shown that the vaccine can be separated into two components on the basis of molecular weight and that both higher (peak A)- and lower (peak B)-molecular-weight fractions were capable of inducing active immunity in mice. The present report indicates that both fractions are also capable of eliciting the production of mouse-protective antibody in rabbits. Agar gel diffusion with antisera to peaks A and B or unfractionated vaccine indicated a common antigenic component among them in addition to an extra antigen in unfractionated vaccine not present in peak B. Passive hemagglutination with antisera to peaks A and B demonstrated high-titer agglutinating antibody only with antiserum to peak A when a method of erythrocyte sensitization for lipopolysaccharide antigens was used. Also, passive hemagglutination was greatly inhibited by small amounts of lipopolysaccharide prepared from the same organism from which the vaccine was made. Both antisera to peaks A and B fixed complement with either A or B antigens. Antisera to peaks A and B, when reacted with peak B antigen, had about the same complement fixation titer (as determined by a quantitative complement fixation test). However, when peak A antigen was used, antiserum to peak A had about twice the complement fixation titer that antiserum to peak B had. These results are consistent with previous observations which suggest that the ribosomal vaccine contains lipopolysaccharide in addition to an unidentified immunogenic principle associated with ribosomes. Furthermore, this immunogen was present in both peaks A and B, but detectable amounts of lipopolysaccharide were present only in peak A. The relative importance of the immunoglobulin G (IgG) and IgM classes of antibodies was also compared. The results indicated that both IgG and IgM isolated from immune rabbit serum are protective in mice. Only IgG precipitated with the vaccine in agar gel diffusion, but both IgG and IgM were active in passive hemagglutination and in complement fixation. The passive hemagglutination titer of the IgM was higher than that of the IgG, but the complement fixation titer of the IgG was higher than that of the IgM. The mouse-protective capability of the IgG and IgM was about the same.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 106013      PMCID: PMC414194          DOI: 10.1128/iai.23.2.509-521.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Biological properties of an immunogenic pneumococcal subcellular preparation.

Authors:  H C Thompson; T K Eisenstein
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

2.  Humoral immunity to Streptococcus pneumoniae induced by a pneumococcal ribosomal protein fraction.

Authors:  C L Swendsen; W Johnson
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

3.  Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans.

Authors:  F B Michel; L Dussourd D'Hinterland; J Bousquet; A M Pinel; G Normier
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

4.  Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella.

Authors:  T K Eisenstein
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

5.  Immunogenic capacity of ribosomes of Salmonella typhi interfered with a flagellin-like material contaminant.

Authors:  G Cofré; I Calderón; G C Mora
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

6.  Cross-protective immunity to Gram-negative bacilli: studies with core glycolipid of Salmonella minnesota and antigens of Streptococcus pneumoniae.

Authors:  L S Young; P Stevens
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

7.  Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.

Authors:  M M Lieberman
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

8.  Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli.

Authors:  S H Zinner; W R McCabe
Journal:  J Infect Dis       Date:  1976-01       Impact factor: 5.226

9.  Antigenic relationship between the common antigen (OEP) of Pseudomonas aeruginosa and Vibrio cholerae.

Authors:  Y Hirao; J Y Homma
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

10.  A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection.

Authors:  M W Fisher
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

View more
  9 in total

1.  Immunogenicity of ribosomes from enzymatically lysed Streptococcus pyogenes.

Authors:  B A Green; W Johnson
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

2.  Kinetic analysis of microbe opsonification based on stimulated polymorphonuclear leukocyte oxygenation activity.

Authors:  R C Allen; M M Lieberman
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

3.  Cell-mediated immunity following experimental vaccinations with Candida albicans ribosomes.

Authors:  R Levy; E Segal; E Eylan; L Barr-Nea
Journal:  Mycopathologia       Date:  1983-11-25       Impact factor: 2.574

4.  Opsonization and phagocytosis of Haemophilus influenzae type B organisms by mouse polymorphonuclear leucocytes and antiribosomal serum.

Authors:  M A Katz; M Solotorovsky; M Lynn
Journal:  Br J Exp Pathol       Date:  1983-06

5.  Ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa.

Authors:  R Gonggrijp; W J Mullers; P J Lemmens; C P van Boven
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

6.  Evidence for the presence of lipopolysaccharide in a ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa.

Authors:  R Gonggrijp; M P Volleberg; P J Lemmens; C P van Boven
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

7.  Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.

Authors:  M M Lieberman; G L Wright; K M Wolcott; D C McKissock-Desoto
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

8.  Protective effect of recombinant murine granulocyte-macrophage colony-stimulating factor against Pseudomonas aeruginosa infection in leukocytopenic mice.

Authors:  T Tanaka; S Okamura; K Okada; A Suga; N Shimono; N Ohhara; Y Hirota; Y Sawae; Y Niho
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

9.  Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders.

Authors:  Matthieu Perreau; Selena Vigano; Florence Bellanger; Céline Pellaton; Guillaume Buss; Denis Comte; Thierry Roger; Christine Lacabaratz; Pierre-Alexandre Bart; Yves Levy; Giuseppe Pantaleo
Journal:  J Exp Med       Date:  2014-09-15       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.